Unveiling the value of C‐reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross‐sectional study

Patients with recessive dystrophic epidermolysis bullosa (RDEB) experience numerous complications, which are exacerbated by inflammatory dysregulation and infection. Understanding the immunological mechanisms is crucial for selecting medications that balance inflammation control and immunocompetence...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental dermatology 2024-08, Vol.33 (8), p.e15146-n/a
Hauptverfasser:	Quintana‐Castanedo, Lucía, Sánchez‐Ramón, Silvia, Maseda, Rocío, Illera, Nuria, Pérez‐Conde, Isabel, Molero‐Luis, Marta, Butta, Nora, Arias‐Salgado, Elena G., Monzón‐Manzano, Elena, Zuluaga, Pilar, Martínez‐Santamaría, Lucía, Fernández‐Arquero, Miguel, Llames, Sara G., Meana, Álvaro, Lucas, Raúl, Río, Marcela, Vicente, Ángeles, Escámez, María José, Sacedón, Rosa
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Biomarkers Biomarkers - blood C-reactive protein C-Reactive Protein - metabolism Child Child, Preschool Cross-Sectional Studies cytokines Dystrophic epidermolysis bullosa Epidermolysis bullosa Epidermolysis Bullosa Dystrophica Female Humans Immunocompetence Immunodeficiency Immunoglobulin A Immunoglobulin G Immunoglobulin M immunoglobulins Immunology Infant Infections inflammation Interleukin 13 Interleukin-13 - blood Interleukin-13 - metabolism Interleukin-4 - blood Male Middle Aged Pathophysiology recessive dystrophic epidermolysis bullosa Severity of Illness Index Therapeutic targets Virulence Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!